Andere talen Sage Therapeutics, Inc.

Aandelen

SAGE

US78667J1088

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,94 ^USD	-1,69%		+7,64%	-35,67%

26/04	SAGE THERAPEUTICS, INC. : Truist Securities handhaaft het Neutraal advies	ZM
25/04	Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE	28/04
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M	25/04
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress	25/04
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease	18/04
Top Midday Decliners	17/04
Sector Update: Health Care Stocks Advance Premarket Wednesday	17/04
Sector Update: Health Care	17/04
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	17/04
Top Premarket Decliners	17/04
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	17/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	17/04
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	17/04
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	11/04
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors	26/03
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	26/03
Sage Therapeutics to Present at Upcoming March Investor Conferences	28/02
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	14/02
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sage Therapeutics, Inc.

Aandelen

SAGE

US78667J1088

Andere talen

Filters